-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Neoadjuvant radiotherapy (NRT) is usually used for stage II/III rectal cancer to improve local control without affecting overall survival.
According to the risk stratification criteria and clinical staging, eligible participants of stage II/III rectal cancer were included, preoperatively divided into patients with (high risk) or without (low risk) high-risk factors, and they were randomized to receive short-course radiotherapy (SCRT) ) + Total mesentery resection (TME) or TME alone, divided into the following 4 groups: high-risk patients receiving (HiR) or not receiving (HiS) radiation therapy, low-risk patients receiving (LoR) or not receiving (LoS) radiation therapy .
A total of 401 patients were included in the final analysis.
In summary, the results of the study indicate that stratifying stage II/III rectal cancer based on risk factors and making it a more precise sub-category may result in differences in survival rates and local recurrence control.
Original source:
Xiangbing Deng, et al.
ncbi.
nlm.
nih.
gov/31599809/" target="_blank" rel="noopener">Neoadjuvant Radiotherapy Versus Surgery Alone for Stage II / III Mid-low Rectal Cancer With or Without High-risk Factors: A Prospective Multicenter Stratified Randomized Trial in this message